Výsledky vyhledávání - "Mellissa Nelson"

Abstract P2-16-24: Folate targeted SMDC’s: A possible new treatment alternative for folate receptor expressing TNBC patients

Autor: Marilynn Vetzel, Christopher P. Leamon, Ryan Dorton, Joseph A. Reddy, Alicia Bloomfield, Mellissa Nelson

Publikováno v: Cancer Research. 73:P2-16

Triple negative breast cancer (TNBC) is a subtype characterized by lack of gene expression for the estrogen receptor, progesterone receptor and the Her2/neu protein. Hence, the lack of hormonal or Her2 targeted therapy options makes TNBC difficult to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::033cf7ff9750ddddac05084dea11860e
https://doi.org/10.1158/0008-5472.sabcs13-p2-16-24

Zobrazit plný text záznamu

Abstract 2546: Regulation of CAR-T cell therapy in real time using bispecific small molecule adaptors and monospecific competitors

Autor: Marilynn Vetzel, Christopher P. Leamon, Haiyan Chu, Mellissa Nelson, Yong Gu Lee, Leroy W. Wheeler, Elaine Westrick, Yingjuan Lu, Patrick J. Klein, Philip S. Low

Publikováno v: Cancer Research. 78:2546-2546

Chimeric antigen receptor modified T cell (CAR-T) therapy has revolutionized personalized cancer treatment. The recent FDA approval of two CAR-T therapies for hematological cancers has marked a pivotal milestone in this new era of cellular therapies.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72435d21658b2dbca20d70b093492d09
https://doi.org/10.1158/1538-7445.am2018-2546

Zobrazit plný text záznamu

Abstract LB-109: Adaptor controlled CAR-T cell immunotherapy for treatment of folate receptor-alpha/beta positive solid and liquid tumors

Autor: Marilynn Vetzel, Yingjuan June Lu, Adam Johnson, Patrick J. Klein, Christopher P. Leamon, Haiyan Chu, Leroy W. Wheeler, Philip S. Low, Yong Gu Lee, Elaine Westrick, Michael C. Jensen, Mellissa Nelson, Joshua A. Gustafson, Jason K. Yokoyama

Publikováno v: Cancer Research. 78:LB-109

Personalized immunotherapy has reached a pivotal milestone with the recent approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for certain B-cell malignancies. Other than on-target off-tumor autoimmunity, the commonly seen toxi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e838fedd4adadf3092158f1249d63a7
https://doi.org/10.1158/1538-7445.am2018-lb-109

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání